-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Benzinga·09/29/2026 12:20:10
Listen to the news
Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $40 price target.